EUCTR2014-004353-14-SE进行中（未招募）1 期
Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26-week period off study-drug
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
- •2. Male or female, age 12 to less than 18 years at the time of signing informed consent and less than 18 years at date of randomisation
- •3. BMI corresponding to =30 kg/m^2 for adults by international cut-off points and =the 95th percentile for age and sex (for diagnosis of obesity)
- •4. Stable body weight during the previous 90 days before screening V2 (<5 kg self-reported weight change)
- •5. History of failing to lose sufficient weight with lifestyle modification as judged by the investigator and documented in subject’s medical record
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 228
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pre-pubertal subjects (Tanner stage 1) at screening V2
- •2. Type 1 diabetes mellitus (T1DM)
- •3. Family or personal history of multiple endocrine neoplasia type 2 (MEN2)
- •4. Medullary thyroid carcinoma (MTC)
- •5. History of pancreatitis (acute or chronic)
- •6. Subjects with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine causes)
- •7. Treatment with medications within 90 days before screening V2 that, based on the investigator’s judgement, may cause significant weight change. This should also include treatment with any of the following medications: pramlintide, orlistat, zonisamide, topiramate, lorcaserin, phenteremine, bupropion, naltrexone, glucagon-like peptide-1 (GLP-1) receptor agonists, or metformin (used as treatment for obesity)
- •8. Anti-diabetic treatment other than metformin
- •9. History of major depressive disorder within 2 years before screening V2
研究者
相似试验
进行中（未招募）
1 期
Effect of liraglutide for weight management in pubertal adolescent subjects with obesityMedDRA version: 19.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2014-004353-14-BEovo Nordisk A/S228
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeObesity(Prader-Willi syndrome)MedDRA version: 18.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-004415-37-FRovo Nordisk A/S60
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeEUCTR2014-004415-37-ITovo Nordisk A/S56
进行中（未招募）
1 期
Effect of liraglutide for weight management in children with Prader-Willi SyndromeEUCTR2014-004415-37-NLovo Nordisk A/S60
已完成
3 期
Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period.weight management10003018ObesityNL-OMON47321ovo Nordisk6